Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 07:29 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study to Evaluate Efficacy and Safety of Subcutaneous Abatacept With Steroid Treatment Compared to Steroid Treatment Alone in Adults With Giant Cell Arteritis (GCA)
NCT03192969 · Bristol-Myers Squibb · PHASE3 · withdrawn · last registry update 2017-07-12 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Business objectives have changed” | – | Registry record, Bristol-Myers Squibb |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CD86 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2018-02-26Results posted on the registry: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Abatacept + Placebo (NCT00556439)
- 2018-01-30Phase 3 first posted: University of Nebraska, Methotrexate + Abatacept (NCT03414502)
- 2017-12-21Results posted on the registry: Bristol-Myers Squibb, BMS-188667 + Mycophenolate mofetil (NCT01714817)
- 2017-12-07Results posted on the registry: National Institute of Allergy and Infectious Diseases (NIAID), Belatacept + methylprednisolone (NCT01790594)
- 2017-09-15Results posted on the registry: Boston Children's Hospital, Abatacept (NCT01012492)
- 2017-08-30Results posted on the registry: National Institute of Allergy and Infectious Diseases (NIAID), Alemtuzumab + MMF (NCT01436305)
- 2017-08-28Results posted on the registry: Indiana University, Belatacept (NCT02103855)
- 2017-08-07Results posted on the registry: National Institute of Allergy and Infectious Diseases (NIAID), Anti-thymocyte Globulin (Rabbit) + belatacept (NCT01856257)
- 2017-08-02Results posted on the registry: Bristol-Myers Squibb, Abatacept + Placebo (NCT01860976)
- 2017-07-07Results posted on the registry: Bristol-Myers Squibb, Cyclosporin A + Belatacept Less Intensive Regimen (LI) (NCT00114777)
- 2017-07-06Results posted on the registry: East Carolina University, Belatacept (NCT02078193)
- 2017-06-26Results posted on the registry: Bristol-Myers Squibb, Belatacept (NCT01791491)
- 2017-04-21Also stopped (terminated): National Institute of Allergy and Infectious Diseases (NIAID), Belatacept + Sirolimus (NCT00346151)
- 2017-03-22Phase 3 first posted: AbbVie, Abatacept + Placebo for abatacept (0.9% Sodium Chloride Injection or Solution for Infusion) (NCT03086343)
- 2017-03-13Results posted on the registry: Arthritis & Rheumatic Disease Specialties Research, abatacept (NCT01351480)
- 2017-02-07Also stopped (terminated): Vanderbilt University Medical Center, Abatacept + Placebo (NCT02232880)
- 2017-01-18Results posted on the registry: Bristol-Myers Squibb, Abatacept + Placebo (NCT00095173)
- 2017-01-11Results posted on the registry: Bristol-Myers Squibb, Abatacept (NCT01835470)
- 2017-01-09Also stopped (withdrawn): The Cleveland Clinic, Abatacept (NCT02027298)
- 2017-01-05Results posted on the registry: Bristol-Myers Squibb, Belatacept + Cyclosporine A (NCT00402168)
- 2016-11-23Phase 3 first posted: Bristol-Myers Squibb, Abatacept subcutaneous + Placebo (NCT02971683)
- 2016-09-26Phase 3 first posted: Bristol-Myers Squibb, Abatacept (NCT02915159)
- 2016-08-29Results posted on the registry: Vanderbilt University Medical Center, Abatacept + Placebo (NCT02232880)
- 2016-08-19Results posted on the registry: Bristol-Myers Squibb, Cyclosporine (CsA) + Belatacept LI (less intensive) (NCT00256750)
- 2016-08-16Results posted on the registry: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), CTLA-4 Ig (NCT00505375)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision